Prostate cancer drug 'could be alternative to surgery' for fibroids
Two phase three trials have produced almost identical results showing clear benefit
Daily therapy with the oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, cuts menstrual bleeding by at least half in most women with uterine fibroids, researchers say.
Results from the LIBERTY 2 trial, involving 382 women treated at 99 sites around the world, closely mirror those from the similar-sized LIBERTY 1 trial, first reported nearly two years ago.
Relugolix (Orgovyx, Myovant Sciences) was approved by the US FDA in 2020 as a treatment for advanced prostate cancer and is now
